10.38
Schlusskurs vom Vortag:
$10.15
Offen:
$9.98
24-Stunden-Volumen:
118.75K
Relative Volume:
0.60
Marktkapitalisierung:
$359.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+5.49%
1M Leistung:
+6.79%
6M Leistung:
-58.01%
1J Leistung:
+0.00%
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Firmenname
Rapport Therapeutics Inc
Sektor
Branche
Telefon
857-321-8020
Adresse
1325 BOYLSTON STREET, BOSTON
Vergleichen Sie RAPP mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RAPP
Rapport Therapeutics Inc
|
10.38 | 359.12M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-08 | Eingeleitet | Citizens JMP | Mkt Outperform |
2024-07-02 | Eingeleitet | Jefferies | Buy |
2024-07-02 | Eingeleitet | Stifel | Buy |
2024-07-02 | Eingeleitet | TD Cowen | Buy |
Rapport Therapeutics Inc Aktie (RAPP) Neueste Nachrichten
Rapport therapeutics chief scientific officer sells $81,310 of stock - Investing.com Australia
Rapport therapeutics chief scientific officer sells $81,310 of stock By Investing.com - Investing.com South Africa
KLP Kapitalforvaltning AS Purchases Shares of 1,900 Rapport Therapeutics (NASDAQ:RAPP) - Defense World
48,452 Shares in Rapport Therapeutics (NASDAQ:RAPP) Acquired by Norges Bank - Defense World
Comparing Rapport Therapeutics (RAPP) & The Competition - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Coverage Initiated at JMP Securities - Defense World
JMP Securities Initiates Coverage of Rapport Therapeutics (RAPP) with Market Outperform Recommendation - Nasdaq
Citizens JMP sets $28 target for Rapport Therapeutics stock By Investing.com - Investing.com Canada
(RAPP) Investment Analysis - news.stocktradersdaily.com
nCino Posts Weak Earnings, Joins Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Rapport Therapeutics: Too Early To Be Interesting (NASDAQ:RAPP) - Seeking Alpha
Swiss National Bank Purchases New Stake in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Analyzing Neurogene (NASDAQ:NGNE) & Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
(RAPP) Long Term Investment Analysis - news.stocktradersdaily.com
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Vanda Pharmaceuticals (NASDAQ:VNDA) and Rapport Therapeutics (NASDAQ:RAPP) Financial Contrast - Defense World
Rapport Therapeutics to present data at 2025 AAN meeting - TipRanks
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting - GlobeNewswire
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting - GlobeNewswire Inc.
Several Insiders Invested In Rapport Therapeutics Flagging Positive News - simplywall.st
Positive Signs As Multiple Insiders Buy Rapport Therapeutics Stock - Yahoo
Insider Buying: Rapport Therapeutics Chief Financial Officer Bought US$101k Of Shares - Yahoo Finance
Rapport Therapeutics director Wendy Young acquires $61,249 in stock By Investing.com - Investing.com India
Rapport Therapeutics CFO Troy Ignelzi buys $100,988 in stock - Investing.com
Rapport Therapeutics CFO Troy Ignelzi buys $100,988 in stock By Investing.com - Investing.com India
Rapport Therapeutics Executives Acquire Shares - TradingView
Rapport Therapeutics director Wendy Young acquires $61,249 in stock - Investing.com
Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Rapport Therapeutics Reports Q4 Net Loss Of $19.98 Mln - Nasdaq
Rapport Therapeutics, Inc. SEC 10-K Report - TradingView
Rapport Therapeutics reports Q4 EPS (57c) vs. ($8.01) last year - TipRanks
Rapport Therapeutics Inc Q4 Net Loss $20.0 Million -March 11, 2025 at 07:20 am EDT - Marketscreener.com
Rhumbline Advisers Has $182,000 Stock Position in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
New York State Common Retirement Fund Acquires New Position in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
(RAPP) On The My Stocks Page - Stock Traders Daily
Head of R&D Robert Lenz to leave Neumora - BioCentury
Rapport Therapeutics appoints new chief medical officer By Investing.com - Investing.com Canada
Rapport Therapeutics, Inc. Announces Appointment of Jeffrey Sevigny as Chief Medical Officer - Marketscreener.com
Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development - The Manila Times
Rapport Therapeutics appoints new chief medical officer - Investing.com
Rapport Therapeutics Announces Appointment of Dr. Jeffrey - GlobeNewswire
Rapport Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Rapport Therapeutics (RAPP) Expected to Announce Earnings on Thursday - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 8.5%Here's What Happened - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap UpHere's Why - MarketBeat
How To Trade (RAPP) - Stock Traders Daily
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 5.6%What's Next? - MarketBeat
Jennison Associates LLC Acquires Shares of 62,287 Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Finanzdaten der Rapport Therapeutics Inc-Aktie (RAPP)
Es liegen keine Finanzdaten für Rapport Therapeutics Inc (RAPP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):